Cocrystal Pharma, Inc. (COCP): Price and Financial Metrics
COCP Price/Volume Stats
Current price | $2.21 | 52-week high | $3.26 |
Prev. close | $2.41 | 52-week low | $1.33 |
Day low | $2.21 | Volume | 12,300 |
Day high | $2.44 | Avg. volume | 60,417 |
50-day MA | $2.09 | Dividend yield | N/A |
200-day MA | $1.97 | Market Cap | 22.48M |
COCP Stock Price Chart Interactive Chart >
Cocrystal Pharma, Inc. (COCP) Company Bio
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
COCP Price Returns
1-mo | 18.82% |
3-mo | 25.57% |
6-mo | -1.34% |
1-year | 32.34% |
3-year | -70.10% |
5-year | -62.88% |
YTD | 9.41% |
2024 | 17.29% |
2023 | -11.68% |
2022 | -75.00% |
2021 | -52.21% |
2020 | 174.47% |
Continue Researching COCP
Here are a few links from around the web to help you further your research on Cocrystal Pharma Inc's stock as an investment opportunity:Cocrystal Pharma Inc (COCP) Stock Price | Nasdaq
Cocrystal Pharma Inc (COCP) Stock Quote, History and News - Yahoo Finance
Cocrystal Pharma Inc (COCP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...